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Summary 
The proficiency study for quinolones in egg was organized in accordance with ISO/IEC Guide 43-1 and 
43-2 and ILAC-G13, and under accreditation.  
 
For this proficiency study, four test materials were prepared: 
• A blank egg material; 
• A blank egg material containing possibly interfering compounds to test the selectivity of the applied 
methods;  
• An egg material containing about 70 µg/kg oxolinic acid (incurred) and about 50 µg/kg of both 
ciprofloxacin and enrofloxacin (spiked); 
• An egg material containing about 125 µg/kg flumequine (incurred). 
During homogeneity testing, all materials proved to obtain sufficient homogeneity for proficiency 
testing. The stability test demonstrated that no significant loss of any of the compounds occurred during 
the timescale of the proficiency test. 
 
Eighteen laboratories subscribed for participation in the proficiency study quinolones in egg including 
three National Reference Laboratories. Fifteen laboratories managed to submit valid results within the 
timeframe of the stability study. Five of the participating laboratories applied a validated method which 
was accredited in all cases.  
 
The minority of participants applied a validated method for the analysis of quinolones in egg. Only three 
laboratories reported values for CCα and CCß. It is noted that reported values for CCα and CCß 
severely differ among the laboratories. Most likely these differences are due to different ways of 
calculation. From the reported values of CCα it is concluded that some laboratories calculated CCα 
based on a self set MRL, others applied the zero tolerance approach. From this it is concluded that 
laboratories cope in very different ways with the non existence of MRL values for quinolones in egg. 
MRLs are set for other matrices. Discussion on this issue resulting in clear legislation is of main 
importance for obtaining a uniform approach within Europe. 
 
None of the laboratories detected any quinolones in the blank material nor in the material containing 
possibly interfering compounds. It is concluded that the applied methods are all satisfactory specific for 
the quantitative and confirmative analysis of ciprofloxacin (CIF), enrofloxacin (ENF), oxolinic acid 
(OXA) and flumequine (FLU) in egg.  
One laboratory detected norfloxacin instead of ciprofloxacin in the two samples that contain quinolones. 
This is considered as a false positive as well as a false negative result because CIF was included in their 
method.  
 
The laboratory's performance for the materials containing quinolones are summarized in Table 1.  
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Table 1. Summary of the laboratory's performance of the materials containing quinolonens 
Compound No. of satisfactory results 
 
Assigned value (X) 
(µg/kg) 
Uncertainty of X  
(µg/kg) 
No. of labs that 
reported results Accuracy 
CIF 46.4 1.10 13 10 
ENF 48.0 1.47 15 14 
OXA 73.2 1.99 11 11 
FLU 124.9 4.27 13 13 
 
For OXA and FLU all reported results were satisfactory. For CIF and ENF some questionable and 
unsatisfactory results are observed. The occurrence of questionable or unsatisfactory results could not be 
explained by the applied detection or sample preparation technique. 
However, 75% of the total of calculated za-scores is between -0.5 and 0.5 indicating excellent accuracy 
for most laboratories. Therefore it is concluded that the performance of most laboratories is excellent 
regarding the quantification of quinolones in egg.  
 
One laboratory detected norfloxacin in one of the duplicate analysis of both samples of material Egg-03. 
This is considered as a false positive result. The same laboratory did not detect CIF in the samples of 
material Egg-03. This is considered as a false negative result. 
 
In this proficiency study 73% of the laboratories showed optimal performance in terms of accuracy and 
the absence of false positive and false negative findings. 
 
Based on the results of this proficiency study it is concluded that: 
• regarding B group substances for which no MRL is set in a specific matrix, legislation should be 
clarified to obtain a uniform way for the determination of CCα and CCß within the EU and with this 
a uniform way of characterizing the samples in terms of compliant and non compliant.. 
• for most laboratories additional effort is needed to validate the analysis of quinolones in egg to be 
able to report results including a value for measurement uncertainty. 
• Additional effort is needed by some laboratories to include oxolinic acid in the method of analysis 
for quinolones in egg because, officially, oxolinic acid is the only quinolone registered for 
medication of laying hens in the EU and for which an MRL is established. 
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1 Introduction 
1.1 Proficiency testing 
Proficiency testing is conducted to provide laboratories with a powerful tool to evaluate and 
demonstrate the reliability of the data that is produced. Next to validation and accreditation, proficiency 
testing is an important requirement of the EU Additional Measures Directive 93/99/EEC [1] and is 
increasingly important in the new ISO 17025:2005 [2].  
No internationally focused proficiency studies regarding the analysis of quinolones in egg that focused 
on the quantitative aspect were organized during the last years: an inter-laboratory quality control for 
this analyte-matix combination was lacking. Therefore, RIKILT decided to organize a proficiency study 
regarding this subject.  
 
The aim of this proficiency study was to give laboratories the possibility to evaluate or demonstrate 
their competence for the analysis of quinolones in egg. Furthermore the specificity of the applied 
methods is evaluated by including possibly interfering compounds in the proficiency study. 
This study also provided an evaluation of the methods applied for quantitative and confirmatory 
analysis of quinolones in egg. Additionally, this proficiency study was organized to get an overview of 
how laboratories are dealing with legislation of group B substances in matrices for which no maximum 
residue limit (MRL) is set.  
 
This proficiency study was conducted in accordance with guidelines ISO/IEC 43-1 [3], ISO/IEC 43-2 
[4] and ILAC-G13 [5] and was organized under accreditation by RIKILT - Institute of Food Safety. 
1.2 Quinolones 
The discovery of the synthetic antibacterial agent nalidixic acid in 1962 marks the beginning of decades 
of quinolone development for human and veterinary use [6, 7, 8]. Nalidixic acid was discovered as a by-
product of the production of the anti-malaria drug chloroquine. Nalidixic acid was found to be a rapid 
bactericidal agent by inhibition of the bacterial DNA gyrase synthesis [9]. Nalidixic acid is active 
against the majority of Gram-negative bacteria. Unfortunately it is not active against Pseudomonas 
aeruginosa (responsible for causing numerous infections), Gram-positive organisms and anaerobes. In 
addition, the clinical use of nalidixic acid is limited, because administration results in low drug 
concentrations in serum and tissues. Furthermore, resistance to nalidixic acid developed rapidly in 
numerous organisms. Derivatisation products of nalidixic acid, like oxolinic acid represented only 
marginal improvements over nalidixic acid. 
 
In 1976, the development of flumequine, the first fluoroquinolone, offered significant improvement. 
This monofluoroquinolone indicated that the addition of a fluor atom in the molecule improved Gram-
positive activity. In 1978 norfloxacin, a monofluorinated quinolone with a piperazinyl side-chain was 
developed. This fluoroquinolone has a longer half-time, less protein binding and improved Gram-
negative activity compared to the earlier developed compounds. Still the pharmacokinetic profile and 
activity were not adequate for systemic use [10]. 
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Very successful and widely used compounds of the fluoroquinolone group are ciprofloxacin, developed 
in 1981 and its metabolite enrofloxacin that is mainly used as veterinary drug [11]. These compounds 
are active against a broad spectrum of Gram-positive as well as Gram-negative species, including 
Pseudomonas aeruginosa. Following oral administration, the drug is well distributed through the body 
with high concentrations in most tissues. 
 
Gram-positive staphylococci became a major problem with increasing resistance to antibiotic 
compounds like ß-lactams and macrolides. Also for quinolones resistance in human pathogens was 
demonstrated [12]. Therefore, the search for new fluoroquinolones continued, aiming for improved 
activity for ß-lactam, macrolide and quinolone resistant strains, and activity against Gram-positive 
staphylococci and anaerobes. This resulted in the development of fourth-generation quinolones. 
1.2.1 Quinolones in animal health 
The most notable fluoroquinolones used in veterinary medicine worldwide include ciprofloxacin, 
danofloxacin, enrofloxacin, marbofloxacin, norfloxacin and sarafloxacin [9]. Data gathered by The 
World Health Organization indicate that the use of quinolones differs greatly as regards animal species 
and geographical spread [13, 14].  
Quinolones have a very broad clinical application in livestock, poultry, fish and domestic animals in the 
treatment and prevention of respiratory, enteric and urinary tract infections [14].  
 
Quinolone resistance has multiple mechanisms and significant clinical impact. Mutations may occur 
rapidly during fluoroquinolone therapy and may be the most significant factor limiting the use of these 
antimicrobials [15]. The toxicity of quinolones is mild at therapeutic doses and generally consists of 
gastrointestinal disturbances such as nausea and diarrhoea. At higher doses the central nervous system is 
affected resulting in dizziness, depression or insomnia [9].  
 
The distribution and metabolism of enrofloxacin was studied in rats [15]. After oral administration 
enrofloxacin was well absorbed. The substance was widely distributed to all tissues with the highest 
concentration in liver and kidney. Elimination was rapid via both urine and faeces. Ciprofloxacin was 
indicated as the major metabolite of enrofloxacin [15]. The occurrence of metabolism of other 
quinolone compounds was not demonstrated. 
1.2.2 Quinolones in egg 
According to EU regulations, all substances for veterinary use need to be included in Annexes I, II or III 
of Council Regulation (ECC) No 2377/90 [13]. Quinolones are included in Annex I: pharmacologically 
active veterinary products for which a Maximum Residue Limit (MRL) is established. However, 
regarding quinolones in the matrix egg, only a MRL for oxolinic acid is established. Therefore, 
officially the use of other quinolones in laying hens is prohibited. A zero tolerance is applicable and the 
characterization of samples in terms of ‘compliant’ or ‘non compliant’ should be made based on this.  
However, the absence of MRLs for quinolones in egg is subject to discussion. The zero tolerance 
approach is in contrast with the establishment of MRLs for quinolones in poultry muscle and other 
matrices because toxiticity and occurrence of resistance for quinolones mainly depend on the intake of 
the quinolones, not on the matrix they are in. Because the intake of egg and poultry can be considered to 
be comparable, maybe equivalent MRLs should be set. Nevertheless, until MRLs are set for quinolone 
residues in egg specifically, a zero tolerance is officially applicable.  
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This inter-laboratory study focuses on oxolinic acid, enrofloxacin (and its metabolite ciprofloxacin) and 
flumequine in egg. The MRLs for these compounds in egg and poultry muscle are presented in Table 2. 
The structures of these fluoroquinolones are presented in Figure 1.  
 
Table 2. MRL in poultry muscle of fluoroquinolones included in the inter-laboratory study [13] 
Compound MRL in egg (µg/kg) MRL in poultry muscle (µg/kg) 
Oxolinic acid 50 100 
Ciprofloxacin - 100* 
Enrofloxacin - 100* 
Flumequine - 400 
* The sum of enrofloxacin and ciprofloxacin should be considered. 
 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Molecular structure of (a) enrofloxacin, (b) ciprofloxacin, (c) oxolinic acid  and (d) flumequine. 
c 
a b 
d 
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2 Test materials 
2.1 Sample preparation 
One blank material, one material containing oxolinic acid (OXA), enrofloxacin (ENF) and ciprofloxacin 
(CIF), one material containing flumequine (FLU) and one material containing possibly interfering 
substances were prepared. 
 
The material used for testing the specificity was prepared by adding methanolic solutions of possibly 
interfering compounds to  a blank material. Fenbendazole sulfon, piroxicam and triclabendazole were 
selected as possibly interfering substances based on their molecular mass. This material is referred to as 
Egg-02. 
 
The material containing OXA, CIF and ENF was prepared from incurred samples containing high levels 
of oxolinic acid. These samples were mixed with blank samples to obtain a relevant level of OXA. CIF 
and ENF were added to this material by addition of methanolic solutions of these compounds. This 
material is referred to as Egg-03. 
The material containing FLU was prepared from incurred samples containing high levels of FLU. These 
samples were mixed with blank samples to obtain a relevant level of FLU. This material is referred to as 
Egg-04.  
Because the MRL for oxolinic acid in egg is half of the MRL of oxolinic acid in poultry muscle, the 
levels of the other compounds in the materials were aimed for about half of the established MRL in 
poultry muscle. 
 
Each of the materials was homogenized by mixing according to in-house standard operating procedures. 
The target amounts of the quinolones in each material is presented in table 3. 
 
Table 3.Target amount of quinolones in the proficiency study test materials  
Material code Amount of 
material (g) 
Compound Level (µg/kg) 
Egg-01 1200 - - 
Egg-02 1200 Fenbandazole sulfon 50 
  Piroxicam 30 
  Triclabendazole 100 
Egg-03 2400 Oxolinic acid 70 
  Enrofloxacin 50 
  Ciprofloxacin 50 
Egg-04 1400 Flumequine 250 
2.2 Sample identification 
The materials were stored in polypropylene containers containing at least 25 gram of sample, yielding a 
total of 40 containers of material Egg-01 and Egg-02, 80 containers of material Egg-03 and 50 
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containers of material Egg-04. The egg samples were randomly coded with a code from 
QUIN/2007/EGG/001 through 210.  
 
For homogeneity and stability testing, 20 randomly selected containers of material Egg-03 and Egg-04 
were used.  
For each laboratory a sample set was prepared consisting of one randomly selected sample of material 
Egg-01, Egg-02 and Egg-04 and two randomly selected samples of material Egg-03. The sample 
numbers belonging to each sample set are presented in Annex 1. 
2.3 Homogeneity study 
The homogeneity of the materials was tested according to The International Harmonized Protocol for 
Proficiency Testing of Analytical Laboratories [16] and ISO/DIS 13528 [17], taking into account the 
insights discussed by Thompson [18] regarding the Horwitz equation.  
With this procedure the between-sample standard deviation (
s
s ) is compared with the target  standard 
deviation derived from the Horwitz equation ( Hσ , §4.3). The materials are considered adequately 
homogeneous if Hs σ3.0s ≤ . 
 
Ten containers of materials Egg-03 and Egg-04 were each analyzed in duplicate for OXA, ENF, CIF and 
FLU to determine the homogeneity of the materials. The results of the homogeneity study and their 
statistical evaluation are presented in Annex 2a through d. All materials were demonstrated to be 
sufficiently homogeneous for all quinolones for use in the proficiency study. The amounts determined 
during the homogeneity study are presented in table 4. 
During the homogeneity study the amount of FLU in material Egg-04 proved to be lower than expected. 
This is probably due to a deviation in the estimated level of the incurred material used for preparation of 
this material. Nevertheless, the determined level of FLU in material Egg-04 is still relevant. Therefore, 
material Egg-03 and Egg-04 were found suitable for application in the proficiency study.  
No extensive homogeneity study was carried out for materials Egg-01 and Egg-02. The homogeneity of 
these materials is not relevant because the results of these materials will not be evaluated in a 
quantitative way. Furthermore, it is assumed that the homogeneity of material Egg-01 and Egg-02 are 
comparable with the homogeneity of the other materials because all materials are homogenized in the 
same way. Nevertheless, three at random selected samples of material Egg-01 and Egg-02 were 
analyzed for ten quinolones. No CIF, ENF, danofloxacin, difloxacin, FLU, marbofloxacin, nalidixic 
acid, OXA or sarafloxacin was detected. It was concluded that materials Egg-01 and Egg-02 are suited 
to use as blank materials in the proficiency study. 
 
Table 4. Determined amount of quinolones in the proficiency study test materials 
Material code Amount of OXA 
(µg/kg) 
Amount of CIF 
(µg/kg) 
Amount of ENF 
(µg/kg) 
Amount of FLU 
(µg/kg) 
Egg-01 - - - - 
Egg-02 - - - - 
Egg-03 72.2 50.9 50.4 - 
Egg-04 - - - 114.4 
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2.4 Participants 
Eighteen laboratories subscribed for participation in the proficiency study quinolones in egg. Most 
participating laboratories are situated in Europe. Of these laboratories three are National Reference 
Laboratories (NRL). 
2.5 Sample distribution 
Each of the participating laboratories received a randomly assigned laboratory code (1 through 18). The 
sample sets with the corresponding number, consisting of five coded samples (Annex 1), were sent to 
the participating laboratories at September 17th 2007. The sample sets were packed in an insulating box, 
containing dry ice or cool packs and were dispatched to the participants immediately by courier. All 
laboratories confirmed the receipt of the samples in good condition (frozen). 
 
The samples were accompanied by a letter (Annex 3) describing the requested analyses, an 
acknowledgement of receipt form and a results form. Furthermore, a reference standard of CIF, 
including a certificate of analysis, was included in the package. The participants were asked to use this 
reference standard in their analysis. With this, the influence of the reference standard on the deviation of 
laboratory results can be determined in the evaluation process. 
 
The laboratories were asked to store the samples until analysis according to their own laboratory’s 
procedure. A duplicate analysis of each sample was requested, resulting in two results for materials Egg-
01, Egg-02 and Egg-04, and four results for material Egg-03. The deadline for sending in results was 
November 2nd 2007, allowing the participants at least six weeks for analysis.  
2.6 Stability 
From the homogeneity data, the amount of quinolone residues in the materials, just after preparation, is 
calculated from the average of the 10 duplicate results.  
The samples for the stability study were stored at -20 °C. On October 9th three containers of material 
Egg-03 and Egg-04 were analyzed in duplicate. On November 19th, after the deadline of the inter-
laboratory study, again three containers of material Egg-03 and Egg-04 were analyzed. For the two 
points in time, the average of the results was calculated.  
The results of the initial analysis were compared with the results of the analyses after the deadline of the 
study, using a Students t-test [20]. The hypothesis for this test is: 
 
)x(E)x(E d0 =  
  
where:   
E( 0x ) = the expected amount of quinolones at the time of the initial analyses;  
E( dx ) = the expected amount of quinolones at time=d. 
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The value t is calculated by: 
 
d0
d0
n
1
n
1
s
xx
t
+
-
=  
 
where:  
0x = the average amount calculated for the initial analyses; 
dx = the average amount calculated for the analyses at time=d; 
s = pooled standard deviation; 
0n = number of results of the initial analyses; 
dn = number of results of the analyses at time=d; 
 
The calculated value t is compared to a critical value (tcrit) derived from a Students-t table with t having 
2nn d0 -+  degrees of freedom [20]. If t < tcrit it is demonstrated that no significant difference between 
the average amount of the analyses at time=d and the initial analyses at time=0 is found. In this case the 
material is considered stable.  
 
The results and statistical evaluation of the stability test are presented in Appendix IV. It was 
demonstrated that no significant loss of CIF, ENF, OXA or FLU occurred at -20°C during the timescale 
of the inter-laboratory study. Therefore it is concluded that during the timescale of the proficiency study  
the samples were suitable for the purpose. 
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3 Applied methodologies 
The participating laboratories applied different sample preparation procedures for the analysis of 
quinolones in egg. Fourteen laboratories applied a quantitative instrumental analysis. A schematic 
overview of the methods applied is presented in Annex 5. 
 
For the instrumental quantitative analysis of quinolones in egg many different extraction solvents or 
mixtures of solvents were used. Six laboratories used a water based solvent (either without addition or 
set at a specific pH) for the extraction. Four laboratories  used acetonitrile as the extraction solvent. The 
pH was set at low pH with formic acid or trifluoro acetic acid or at high pH using ammonia. Two  
laboratories used acified ethanol as the extraction solvent. The other laboratories used mixtures of 
several solvents among which acetonitrile, ethanol and methanol. 
 
For the sample clean up also several different techniques were applied. Seven laboratories applied solid 
phase extraction of which five used C18 material, one a cation exchange material and one an amine 
material. Three laboratories applied a liquid-liquid extraction using ethyl acetate, hexane or 
dichloromethane. 
Four labs only diluted, (ultra)filtered or concentrated (by evaporation) the extracts before analysis. 
 
Two detection techniques were applied for the quantitative analysis of quinolones in egg. Eight 
laboratories applied LC-fluorescence (FLD), in some cases combined with photo diode array detection 
(PDA). Seven laboratories applied LC-MS/MS. Both detection techniques are suited for confirmation of 
the identity of group B substances according to 2002/657/EC [20].  
 
Of the participants that used LC-MS/MS as a detection technique, four used one or more internal 
standards for the quantification of the quinolones. The internal standards used are: 
• deuterated internal standards (d5-norfloxacin, d8-ciprofloxacin) 
• lomefloxacin 
• cinchophen 
 
The laboratories that did not analyze for one or more of the quinolones mentioned in the invitation letter 
are presented in Table 5. It is noted that especially OXA is not included by all laboratories. This 
compound is the only quinolone for which a MRL is established. Therefore, OXA can be expected to be 
used in laying hens. Therefore, this compounds should be included in a method for analysis used in the 
framework of EU regulatory control of residues in egg.  
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Table 5. Overview of laboratories that did not include all quinolones in the analysis. 
Compound Not included by lab 
Danofloxacin 3, 5, 11 
Difloxacin 3, 5, 11 
Flumequine 3, 5 
Marbofloxacin 3, 5, 6, 11, 12, 15 
Nalidixic acid 3,5, 7, 11, 12 
Norfloxacin 3, 6, 11, 12 
Oxolinic acid 3, 5, 11, 12 
sarafloxacin 3, 5, 11 
 
An overview of the method performance characteristics of the participating laboratories is presented in 
Annex 6. All values are presented as reported by the laboratories without any adjustments. Five of the 
15 participating laboratories (i.e. 36%) reported to apply a validated method. All of these laboratories 
have an accreditation for this method.  
 
Amongst the participating laboratories, only three laboratories (2, 8, 12) did report values for CCα for 
quinolones in egg. Hence, only a minority of participating laboratories is able to report their results as 
required by Commission Decision 2002/657/EC [20]. 
It is noted that reported values for CCα and CCß severely differ among the laboratories. Most likely 
these differences exist due to different interpretation of the regulations. Because no MRLs are 
established for quinolones in egg (except for OXA) a zero tolerance applies. Therefore, the value of 
CCα for all quinolones except for OXA should be as low as reasonably possible (Limit of detection of 
the applied method). This complies with the values of CCα reported by lab 8. From the reported values 
of laboratory 2 it is derived that this laboratory calculated CCα based on a reporting limit of 10 µg/kg.  
From this it is concluded that laboratories cope in very different ways with the non existence of MRL 
values for quinolones in egg. MRLs are established for other matrices. Discussion on this issue resulting 
in clear legislation is of main importance for obtaining an uniform approach within Europe.   
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4 Statistical evaluation 
The statistical evaluation was carried out according to the International Harmonized Protocol for the 
Proficiency Testing of Analytical Laboratories [16], elaborated by ISO, IUPAC and AOAC and ISO/DIS 
13528 [17] in combination with the insights published by the Analytical Methods Committee [21, 22] 
regarding robust statistics. 
4.1 Calculation of the assigned value 
The assigned value (X) was determined using robust statistics [21-23]. The advantage of robust statistics 
is that all values are taken into account: outlying observations are retained, but given less weight. 
Furthermore, it is not expected to receive normally distributed data in an inter-laboratory proficiency 
test. When using robust statistics, the data does not have to be normally distributed in contrast to 
conventional outlier elimination methods. 
The robust mean of the reported results of all participants, calculated from an iterative process that is 
based on the median of the reported values, was used as the assigned value [21]. The assigned value is 
therefore a consensus value. 
4.2 Calculation of the uncertainty of the assigned value 
The uncertainty of the assigned value is calculated to determine the influence of this uncertainty on the 
evaluation of the laboratories. A high uncertainty of the assigned value will lead to a high uncertainty of 
the calculated participants za-scores. If the uncertainty of the assigned value and thus the uncertainty of 
the za-score is high, the evaluation could indicate unsatisfactory method performance without any cause 
within the laboratory. In other words, illegitimate conclusions could be drawn regarding the 
performance of the participating laboratories from the calculated za-scores if the uncertainty of the 
assigned value is not taken into account. 
The uncertainty of the assigned value (the robust mean) is calculated from the estimate of the standard 
deviation of the assigned value and the number of values used for the calculation of the assigned value: 
 
n
σˆ
u =  
 
where: 
u = uncertainty of the assigned value;  
n = number of values used to calculate the assigned value;  
σˆ = The estimate of the standard deviation of the assigned value resulting from robust statistics. 
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According to ISO/DIS 13528 [21] the uncertainty of the assigned value (u) is negligible and therefore 
does not have to be included in the statistical evaluation if: 
 
pσ3,0u ≤  
 
where: 
u = The uncertainty of the assigned value; 
p
σ = target standard deviation (§ 4.3). 
 
In case the uncertainty of the assigned value does not comply with this criterion, the uncertainty of the 
assigned value should be taken into account when evaluating the performance of the participants 
regarding the accuracy (§ 4.4). 
4.3 Calculation of the target standard deviation 
According to Commission Decision 2002/657/EC [20], the inter-laboratory coefficient of variation for 
the repeated analysis of a reference or fortified material under reproducibility conditions, shall not 
exceed the level calculated by the Horwitz equation. 
The Horwitz equation, 8495.0H c02.0σ = , presents a useful and widespread applied relation between the 
expected standard deviation under reproducibility conditions, Hσ and the concentration, c. It expresses 
inter-laboratory precision expected in inter-laboratory trials. Therefore, this relation is suitable for 
calculating the target standard deviation, pσ in inter-laboratory trials. 
Thompson [18] demonstrated that the Horwitz equation is not applicable to the lower concentration 
range (<120 µg/kg) as well as to the higher concentration range (>138 g/kg). Therefore a 
complementary model is suggested: 
 
For analyte concentrations <120 µg/kg: 
c22.0σ H =  
 
For analyte concentrations >138 g/kg: 
5.0
H c01.0σ =  
 
where: 
Hσ = expected standard deviation in inter-laboratory trials; 
c  = concentration of the analyte. 
  
The target standard deviation ( pσ ) of CIF, ENF and OXA was determined using the equation for analyte 
concentrations <120 µg/kg. The target standard deviation ( pσ ) of FLU was determined using the 
Horwitz equation. In these calculations c = the assigned value (X) and pH σσ = . 
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4.4 Performance characteristics with regard to the accuracy 
For illustrating the performance of the participating laboratories with regard to the accuracy a za-score is 
calculated. For the evaluation of the performance of the laboratories, the Guidelines of ISO/IEC Guide 
43-1 [3] and ISO/DIS 13528 [17] are applied. According to these guidelines za-scores are classified as 
presented in Table 6.  
 
Table 6: Classification of za-scores 
z ≤ 2 Satisfactory 
2 < z < 3 Questionable 
z ≥ 3 Unsatisfactory 
 
 
If the calculated uncertainty of the assigned value complies with the criterion mentioned in § 4.2, the 
uncertainty is negligible. In this case the accuracy z-score is calculated from: 
 
p
a
σ
Xx
z
-
=  
 
where: 
a
z = accuracy z-score; 
x = the average result of the laboratory; 
X = assigned value; 
pσ = target standard deviation. 
 
However, if the uncertainty of the assigned value does not comply with the criterion mentioned in § 4.2, 
it could influence the evaluation of the laboratories. Therefore in this case, the uncertainty is taken into 
account by calculating the accuracy z-score [13]: 
 
22
p
a
uσ
Xx
'z
+
-
=   
 
where: 
a'z = accuracy z-score taking into account the uncertainty of the assigned value; 
x = the average result of the laboratory; 
X  = assigned value; 
pσ = target standard deviation; 
u  = uncertainty of the assigned value. 
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5 Results and discussion 
Eighteen laboratories subscribed for the participation in the inter-laboratory study for quinolones in egg. 
Thirteen laboratories (i.e. 72 %) managed to submit valid results before the deadline of November 2nd.  
Laboratory 18 analyzed the samples on November 15th and laboratory 13 on November 16th. This was 
still within the time frame of the stability study and thus the results of these laboratories were included 
in the evaluation. Therefore, in total the results of 15 (83%) laboratories are included in the evaluation. 
Laboratory 17 carried out a screening analysis only. Therefore the results of this laboratory are not 
included in the calculation of the assigned value and the uncertainty of the assigned value. However, the 
results of this laboratory are evaluated in perspective of accuracy by calculating z-scores.  
 
All laboratories analyzed the samples in duplicate. The number of laboratories included in the statistical 
evaluation is 12 for ciprofloxacin, 15 for enrofloxacin, 11 for oxolinic acid and 13 for flumequine.  All 
results are used as reported by the laboratories, without any correction or adjustments. However, for 
each reported result only one decimal is presented. Furthermore, laboratory 2 and 18 detected small 
traces of oxolinic acid in the sample of material Egg-04. This is not included in the evaluation.  
 
None of the laboratories detected any quinolones in the blank materials (Egg-01 and Egg-02). Because 
possibly interfering compounds were added to material Egg-02 it is concluded that the applied methods 
are all satisfactory specific for the quantitative and confirmative analysis of CIF, ENF, OXA and FLU in 
egg.  
Laboratory 5 detected norfloxacin in one of the duplicate analysis of both samples of material Egg-03. 
This is considered as a false positive result.  
5.1 Evaluation of the results of ciprofloxacin 
All laboratories, except for laboratory 17 included CIF in their analysis. Laboratory 5 did not detect CIF 
in both samples of material Egg-03, however CIF was included in their method. This is considered as a 
false negative results. Therefore, the evaluation of CIF is based on the results of 13 laboratories. The 
results of CIF as well as the evaluation of it are presented in Annex 8. 
 
The lowest value reported for CIF is 13.5 µg/kg and the highest value is 346.8 µg/kg. The assigned 
value of CIF is 46.4 µg/kg with an uncertainty of 1.10 µg/kg. The uncertainty of the assigned value of 
CIF does not exceeds 0.3σp (§4.2). Therefore, for this material, the influence of the uncertainty of the 
assigned value on the calculated z-scores is negligible. The za-scores for CIF obtained by each 
laboratory were calculated. The results are presented in Annex 8a.  Graphical presentations of the za-
scores are included. 
 
With respect to the accuracy the results of one laboratory (lab 18) is questionable and the result of two 
laboratories (lab 3 and 7) are unsatisfactory. Laboratory 7 reported results of CIF that exceed the 
assigned value by a factor 7. It is noted that this laboratory carried out the analysis of quinolones in egg 
under (a flexible scope) accreditation.  
From the laboratories that reported results, eight used the supplied reference standard of CIF. Based on 
only the results of the laboratories that used the supplied reference standard, the assigned value would 
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be 46.9 µg/kg with an uncertainty of 1.22 µg/kg. Based on only the results of the laboratories that did 
not use the supplied reference standard, the assigned value would be 45.2 µg/kg with an uncertainty of 
1.40 µg/kg. The assigned value as well as the uncertainty of the assigned value is not significantly 
different. Also no significant difference was observed between these values and the assigned value and 
uncertainty calculated from all laboratory results. From this it is concluded that, in this case, the applied 
reference standard is not a main source of uncertainty. 
5.2 Evaluation of the results of enrofloxacin 
All laboratories that sent in results included ENF in their analysis. Therefore the evaluation of ENF is 
based on the results of 15 laboratories. The results of ENF as well as the evaluation of it are presented in 
Annex 9. 
 
For ENF no false negative results occurred. 
 
The lowest value reported for ENF is 17 µg/kg and the highest value is 66.9 µg/kg. The assigned value 
of ENF is 48.0 µg/kg with an uncertainty of  1.47 µg/kg. The uncertainty of the assigned value of ENF 
does not exceeds 0.3σp (§4.2). Therefore, for this material, the influence of the uncertainty of the 
assigned value on the calculated z-scores is negligible. The za-scores for ENF obtained by each 
laboratory were calculated. The results are presented in Annex 9. Graphical representations of the za-
scores are included. 
 
With respect to the accuracy the result of one laboratory (lab 3) is questionable. The difference in 
accuracy among laboratories could not be attributed to differences in the applied sample preparation or 
detection technique. 
5.3 Evaluation of the results of oxolinic acid 
Eleven laboratories that sent in results included OXA in their analysis. The results of OXA as well as the 
evaluation of it are presented in Annex 10. 
 
For OXA no false negative results occurred. 
 
The lowest value reported for OXA is 52 µg/kg and the highest value is 100 µg/kg. The assigned value 
of OXA is 73.2 µg/kg with an uncertainty of  1.99 µg/kg. The uncertainty of the assigned value of OXA 
does not exceeds 0.3σp (§4.2). Therefore, for this material, the influence of the uncertainty of the 
assigned value on the calculated z-scores is negligible. The za-scores for OXA obtained by each 
laboratory were calculated. The results are presented in Annex 10. Graphical representations of the za-
scores are included. 
 
With respect to the accuracy the results of all laboratories are satisfactory; all z-scores (except for 
laboratory 17) are between -1.0 and 1.0 indicating excellent performance regarding the accuracy.  
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5.4 Evaluation of the results of flumequine 
Thirteen laboratories that sent in results included FLU in their analysis. The results of FLU as well as 
the evaluation of it are presented in Annex 11. 
 
For FLU no false negative results occurred. 
 
The lowest value reported for FLU is 80.0 µg/kg and the highest value is 147.2 µg/kg. The assigned 
value of FLU is 124.9 µg/kg with an uncertainty of 4.27 µg/kg. The uncertainty of the assigned value of 
FLU does not exceeds 0.3σp (§4.2). Therefore, for this material, the influence of the uncertainty of the 
assigned value on the calculated z-scores is negligible. The za-scores for FLU obtained by each 
laboratory were calculated. The results are presented in Annex 11. Graphical representations of the za-
scores are included. 
 
With respect to the accuracy the results of all laboratories are satisfactory. 
5.5 Overall evaluation 
From the 15 laboratories 11 (i.e. 73%) showed optimal performance for the analysis of quinolones in 
egg with respect to the accuracy and the occurrence of false positive and false negative results. An 
overview of the amount of satisfactory results is presented in table 7. A complete overview of z-scores is 
given in Annex 12. 
  
Table 7 Overview of the amount of satisfactory results for accuracy 
Compound No. laboratories that 
reported results 
No. of satisfactory 
results for accuracy 
No. of questionalble 
results for accuracy 
No. of unsatisfactory 
results for accuracy 
Ciprofloxacin 13 10 1 2 
Enrofloxacin 15 14 0 1 
Oxolinic acid 11 11 0 0 
Flumequine 13 13 0 0 
 
For CIF one questionable and two unsatisfactory results for accuracy are obtained. For ENF one 
laboratory obtained questionable results regarding reproducibility.  
Laboratory 7 reported an unsatisfactory result for CIF that is a factor 7 above the assigned value, . The 
results of the other quinolones of this laboratory are satisfactory with z-scores between -0.41 and 0.29. 
Laboratory 18 reported questionable results for CIF. However, the results for the other quinolones are 
satisfactory with z-scores between -0.03 and 0.36. In this proficiency test laboratory 3 and 13 have a 
bias to lower results for all compounds included in their analysis.  
 
In 2006 RIKILT organized a proficiency test regarding the analysis of quinolones in poultry muscle. In 
this study, fifteen laboratories reported results of which seven also participated in the proficiency test 
regarding the matrix egg presented in this report. It is noted that in 2006 the majority of laboratories 
reported to have a validated (87%) and accreditated (80%) method for the analysis of quinolones in 
poultry. In 2007 only 38% of the laboratories reported to have a validated method for quinolones in egg. 
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In the proficiency study of quinolones in poultry muscle of 2006 CIF and ENF were also included in the 
materials. In this former study in some materials the levels of CIF and ENF were comparable to the 
levels of CIF and ENF in the present study regarding the matrix egg. 
The assigned values and relative standard deviation of the assigned values, as well as the amount of 
participants and satisfactory scores are presented in table 8.  
 
Table 8 Overview of the results of the proficiency study of quinolones in poultry muscle (2006) and 
quinolones in egg (2007) 
Description PT quinolones in poultry muscle 2006 PT quinolones in egg 2007 
 Ciprofloxacin Enrofloxacin Ciprofloxacin Enrofloxacin 
Assigned value (X) (µg/kg) 38.1  68.1 46.4 48.0 
Relative standard deviation of X (%) 33.0 28.9 8.6 11.5 
No. of results 15 15 13 15 
No. of satisfactory results (accuracy) (%) 73 80 77 92 
 
It is clear that the relative standard deviation of the assigned value of CIF and ENF in the proficiency 
study of quinolones in poultry muscle is significantly higher compared to the proficiency study of 
quinolones in egg. It is concluded that in general the accuracy of the method of analysis of egg is better 
than for the analysis of poultry muscle or much development took place during the last year to increase 
the performance of the analysis of quinolones in general.  
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6 Conclusions 
Eighteen laboratories subscribed for participation in the proficiency study quinolones in egg including 
three are National Reference Laboratories. Fifteen laboratories managed to submit valid results within 
the timeframe of the stability study. Five of the participating laboratories applied a validated method 
which was accredited in all cases.  
 
The minority of participants applied a validated method for the analysis of quinolones in egg. Only three 
laboratories reported values for CCα and CCß. It is noted that reported values for CCα and CCß 
severely differ among the laboratories. Most likely these differences are due to different ways of 
calculations. From the reported values of CCα it is concluded that some laboratories calculated CCα 
based on a self set MRL, others applied the zero tolerance approach. From this it is concluded that 
laboratories cope in very different ways with the non existence of MRL values for quinolones in egg. 
MRLs are set for other matrices. Discussion on this issue resulting in clear legislation is of main 
importance for obtaining a uniform approach within Europe.   
 
None of the laboratories detected any quinolones in the blank material nor in the material containing 
possibly interfering compounds. It is concluded that the applied methods are all satisfactory specific for 
the quantitative and confirmative analysis of CIF, ENF, OXA and FLU in egg.  
One laboratory detected norfloxacin instead of ciprofloxacin in the two samples that contain quinolones. 
This is considered as a false positive result. The same laboratory did not detect CIF in the material that 
contains CIF. However, CIF was included in their method. This is considered as a false negative result.  
 
Unless the fact that for CIF and ENF some non satisfactory results are observed, 75% of the total of 
calculated za-scores is between -0.5 and 0.5 indicating excellent accuracy. The occurrence of 
questionable or unsatisfactory results could not be explained by the applied detection or sample 
preparation technique. For oxolinic acid and flumequine all reported results were satisfactory. 
In this proficiency study 73% of the laboratories showed optimal performance in terms of accuracy and 
the absence of false positive and false negative findings. 
 
Based on the results of this proficiency study it is concluded that: 
• Regarding B group substances for which no MRL is set in a specific matrix, legislation should be 
clarified to obtain a uniform way for the determination of CCα and CCß within the EU and with this 
a uniform way of characterizing the samples in terms of compliant and non compliant. 
• For most laboratories additional effort is needed to validate the analysis of quinolones in egg to be 
able to report results including a value for measurement uncertainty. 
• Additional effort is needed by some laboratories to include oxolinic acid in the method of analysis 
for quinolones in egg because, officially, oxolinic acid is the only quinolone registered for 
medication of laying hens in the EU and for which an MRL is established. 
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Annex 1  Codification of the samples 
 
Sample set Material Egg-01 Material Egg-02 Material Egg-03 Material Egg-04 
1 194 195 120 012 
   167  
2 025 119 98 038 
   165  
3 159 022 086 100 
   202  
4 121 208 047 026 
   085  
5 103 092 131 196 
   163  
6 68 044 024 052 
   035  
7 123 197 153 142 
   156  
8 013 182 011 034 
   058  
9 050 093 029 127 
   160  
10 008 064 097 095 
   112  
11 094 032 019 130 
   199  
12 188 105 007 081 
   189  
13 110 028 076 117 
   178  
14 136 115 031 184 
   140  
15 053 063 010 144 
   161  
16 027 183 099 060 
   125  
17 016 045 155 055 
   200  
18 141 179 059 048 
   192  
19 175 082 001 201 
   170  
20 111 177 018 137 
   069  
* all sample number start with QUIN/2007/EGG/ 
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Annex 2a  Statistical evaluation of homogeneity data of material Egg-03 for 
oxolinic acid 
 
 Oxolinic acid (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 63.8 66.6 
2 68.4 69.2 
3 72.1 72.6 
4 71.6 74.7 
5 76.7 70.6 
6 73.6 70.8 
7 70.3 73.0 
8 73.9 72.0 
9 74.4 77.6 
10 77.9 74.0 
Grand mean 72.2 
Cochran’s test   
C 0.371 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 15.9 
sx 3.21 
sw 2.24 
ss 2.79 
Critical = 0.3 Hσ  4.76 
ss < critical? ACCEPTED 
 
No danofloxacin, difloxacin, flumequine, marbofloxacin, nalidixic acid, norfloxacin or sarafloxacin 
were detected in the samples.  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2b  Statistical evaluation of homogeneity data of material Egg-03 for 
ciprofloxacin 
 
 ciprofloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 48.9 43.6 
2 54.3 57.1 
3 64.1 50.2 
4 50.8 46.5 
5 52.3 48.4 
6 56.3 54.1 
7 59.1 46.7 
8 45.2 52.3 
9 39.3 52.2 
10 43.7 53.8 
Grand mean 50.9 
Cochran’s test   
C 0.262 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 11.2 
sx 4.04 
sw 6.09 
ss 0.00 
Critical = 0.3 Hσ  3.36 
ss < critical? ACCEPTED 
 
No danofloxacin, difloxacin, flumequine, marbofloxacin, nalidixic acid, norfloxacin or sarafloxacin was 
detected in the samples.  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2c   Statistical evaluation of homogeneity data of material Egg-03 for 
enrofloxacin 
 
 Enrofloxacin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 57.0 54.4 
2 56.6 51.6 
3 52.0 45.5 
4 52.3 48.7 
5 50.4 43.6 
6 48.8 40.3 
7 52.9 48.8 
8 47.6 48.0 
9 44.3 49.7 
10 62.9 54 
Grand mean 50.5 
Cochran’s test   
C 0.240 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 11.1 
sx 4.39 
sw 4.08 
ss 3.30 
Critical = 0.3 Hσ  3.33 
ss < critical? ACCEPTED 
 
No danofloxacin, difloxacin, flumequine, marbofloxacin, nalidixic acid, norfloxacin or sarafloxacin was 
detected in the samples.  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2d  Statistical evaluation of homogeneity data of material Egg-04 for 
flumequine 
 
 Flumequine (µg/kg) 
Sample No. Replicate 1 Replicate 2 
1 116.9 120.1 
2 111.5 107.5 
3 113.6 109.5 
4 111.0 114.0 
5* 130.1 110.2 
6 112.1 110.4 
7 113.4 109.1 
8 120.8 116.1 
9 115.3 117.5 
10 122.6 118.1 
Grand mean 115.0 
Cochran’s test   
C 0.765 
Ccrit 0.602 
C < Ccrit? OUTLIER sample no. 5 
After removal of Sample no. 5 
Grand mean 114.4 
Cochran’s test 
C 0.187 
Ccrit 0.638 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 25.2 
sx 4.01 
sw 2.59 
ss 3.56 
Critical = 0.3 Hσ  7.55 
ss < critical? ACCEPTED 
 
No ciprofloxacin, danofloxacin, difloxacin, enrofloxacin, marbofloxacin, nalidixic acid, norfloxacin, 
oxolinic acid or sarafloxacin was detected in the samples.  
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 3  Instruction letter 
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Annex 4a Statistical evaluation of stability data of material Egg-03 
 
Statistical evaluation for ciprofloxacin in material Egg-03 
Date of storage 
at -20 °C 
Time at -20°C 
(days) 
Average amount  
(µg/kg) 
n st. dev 
(µg/kg) 
t tcrit t < tcrit 
Aug 7, 2007 0 50.9 20     
Nov 19, 2007 104 50.3 6 9.27 0.14 2.06 ACCEPTED 
 
Statistical evaluation for enrofloxacin in material Egg-03 
Date of storage 
at -20 °C 
Time at -20°C 
(days) 
Average amount  
(µg/kg) 
n st. dev 
(µg/kg) 
t tcrit t < tcrit 
Aug 7, 2007 0 50.5 20     
Nov 19, 2007 104 51.0 6 10.90 0.10 2.06 ACCEPTED 
 
Statistical evaluation for oxolinic acid in material Egg-03 
Date of storage 
at -20 °C 
Time at -20°C 
(days) 
Average amount  
(µg/kg) 
n st. dev 
(µg/kg) 
t tcrit t < tcrit 
Aug 7, 2007 0 72.2 20     
Nov 19, 2007 104 70.1 6 5.09 0.90 2.06 ACCEPTED 
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Annex 4b  Statistical evaluation of stability data of material Egg-04 
 
Statistical evaluation for flumequine in material Egg-04 
Date of storage 
at -20 °C 
Time at -20°C 
(days) 
Average amount  
(µg/kg) 
n st. dev 
(µg/kg) 
t tcrit t < tcrit 
Aug 22, 2007 0 114.4 18     
Nov 19, 2007 89 110.6 6 6.24 1.31 2.07 ACCEPTED 
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Annex 5 Overview of the applied methods 
 
Lab 
code 
Extraction Sample purification Internal standard Detection method Quinolones not analysed for 
2 McIlvain buffer Add NaCl, LLE (ethyl acetate), evaporation of solvent, 
reconstitution, membrane filtration 
 LC-MS/MS  
3 acetonitrile, acetic acid, 
ethanol 
Evaporation of solvent, reconstitution, LLE (hexane), 
evaporation of solvent, reconstitution, filter 
 LC-FLD Danofloxacin, difloxacin, flumequine, 
marbofloxacin, nalidixic acid, 
norfloxacin, oxolinic acid, sarafloxacin 
4 HCl SPE (C18), partial evaporation of solvent, adjustment of 
solvent volume 
 LC-MS/MS 
LC-PDA/FLD 
 
5 Ammonia (25%), 
Acetonitrile 
LLE (dichloromethane)  LC-FLD Danofloxacin, difloxacin, flumequine, 
marbofloxacin, nalidixic acid, oxolinic 
acid, sarafloxacin 
6 Acetic acid, ethanol (2x) Partial evaporation of solvent, adjustment of solvent 
volume, dilution 
 LC-FLD Marbofloxacin, norfloxacin 
7 Water SPE (OASIS HLB), evaporation of solvent d5-norfloxacin LC-MS/MS Nalidixic acid 
8 Acetonitrile, trifluoroacetic 
acid 
SPE (C18), evaporation of solvent, reconstitution  LC-FLD  
9 Acetonitrile, formic acid Evaporation of solvent, reconstitution, SPE (Oasis 
MCX)  
d8-ciprofloxacin 
d5-norfloxacin 
LC-MS/MS  
11 Water Filter  LC-FLD Danofloxacin, difloxacin, 
marbofloxacin, nalidixic acid, 
norfloxacin, oxolinic acid, sarafloxacin 
12 Phosphate buffer (pH=7.4) Protein precipitation (phosphoric acid), filtration, SPE 
(DSC 18), evaporation of solvent, reconstitution 
 LC-FLD Marbofloxacin, nalidixic acid, 
norfloxacin, oxolinic acid 
13 Ethanol, acetic acid SPE (NH2, PRS), evaporation of solvent, reconstitution  LC-MS/MS  
15 Water, methanol, 
acetonitrile, phosphoric 
acid, ultrasonic bath, 45 °C 
Evaporation of organic solvent, SPE (OASIS HLB), 
evaporation of solvent, reconstitution 
 LC-FLU-PDA Marbofloxacin 
16 Water Filtration, ultrafiltration lomefloxacin, cinchophen LC-MS/MS  
17    ELISA  
18 Acetonitrile Evaporation of solvent, reconstitution lomefloxacin, cinchophen LC-MS/MS   
NM = not mentioned 
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Annex 6 Overview of method characteristics as reported by the participants  
 
  Ciprofloxacin Enrofloxacin Oxolinic acid Flumequine 
Lab 
code 
Validation / 
accreditation 
CCα 
(µg/kg) 
CCß 
(µg/kg) 
CCα 
(µg/kg) 
CCß 
(µg/kg) 
CCα 
(µg/kg) 
CCß 
(µg/kg) 
CCα 
(µg/kg) 
CCß 
(µg/kg) 
2 Yes / Yes 12.23 13.77 12.19 13.70 10.77 11.31 11.15 11.95 
3 No / No         
4 Yes / Yes         
5 No / No         
6 Yes / Yes         
7 Yes / Yes         
8 Yes / Yes 1.017 1.832 1.095 1.964 0.10 0.176 0.323 0.534 
9 No / No         
11 No / No         
12 No / No 10 20 10 20   40 50 
13 No / No  ≤50  ≤50  ≤50  ≤50 
15 No / No         
16 No / No         
17 No / No         
18 No / No         
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Annex 6 Overview of method characteristics as reported by the participants (continued) 
 
  Ciprofloxacin Enrofloxacin Oxolinic acid Flumequine 
Lab 
code 
Validation / 
accreditation 
LOD 
(µg/kg) 
LOQ 
(µg/kg) 
LOD 
(µg/kg) 
LOQ 
(µg/kg) 
LOD 
(µg/kg) 
LOQ 
(µg/kg) 
LOD 
(µg/kg) 
LOQ 
(µg/kg) 
2 Yes / Yes 0.23 0.47 0.50 1.00 0.21 0.42 0.07 0.14 
3 No / No 1 2 1 2     
4 Yes / Yes 10 20 10 20 10 20 10 20 
5 No / No  10  10     
6 Yes / Yes  6  6  10  10 
7 Yes / Yes  5  5  5  5 
8 Yes / Yes 0.06 0.15 0.03 0.06 12.53 22.31 4.06 8.58 
9 No / No  20  20  20  20 
11 No / No 3  6    8  
12 No / No         
13 No / No <10  <10  <10  <10  
15 No / No         
16 No / No         
17 No / No   9 12 4 6 3.5 4 
18 No / No 1  1  1  1  
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Annex 7  Overview of false positive and false negative results 
 
 
False positive results 
Lab code Sample code Material Analyte found Replicate 1 (µg/kg) Replicate 2 (µg/kg) 
Lab5 QUIN/2007/EGG/131 Egg-03 Norfloxacin - 39 
 QUIN/2007/EGG/163 Egg-03 Norfloxacin - 43 
 
 
 
False negative results 
Lab code Sample code Material Analyte 
Lab5 QUIN/2007/EGG/131 Egg-03 Ciprofloxacin 
 QUIN/2007/EGG/163 Egg-03 Ciprofloxacin 
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Annex 8  Results for the analysis of ciprofloxacin in egg (material Egg-03) 
 
Ciprofloxacin 
Assigned value: 46.4 µg/kg 
Uncertainty of assigned value: 1.10 µg/kg 
Target standard deviation (Horwitz, Thompson):  10.2 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average  sr sW za-score 
2 41.0 50.1 44.6 42.7 44.6 3.80 3.80 -0.18 
3 16.7 14.6 13.5 13.8 14.7 0.87 1.54 -3.11 
4 43.6 44.9 50.9 47.7 46.8 1.41 3.71 0.04 
6 43.7 50.0 43.1 50.5 46.8 3.97 3.97 0.04 
7 323.5 346.8 317.0 316.7 326.0 9.51 14.58 27.38 
8 43.6 46.1 44.2 46.2 45.0 1.31 1.31 -0.14 
9 43.0 45.0 46.0 42.0 44.0 1.83 1.83 -0.24 
11 51.4 48.3 48.1 48.6 49.1 1.28 1.40 0.26 
12 46.8 47.7 45.4 46.1 46.5 0.47 1.11 0.01 
13 17.0 41.0 35.0 62.0 38.8 14.75 17.29 -0.75 
15 44.2 46.5 45.4 44.5 45.2 1.01 1.01 -0.12 
16 53.2 50.9 42.8 50.8 49.4 3.40 4.42 0.29 
18 61.0 81.0 61.0 75.0 69.5 9.97 9.97 2.26 
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Annex 8  Results for the analysis of ciprofloxacin in egg (material Egg-03) 
(continued) 
 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of za-score              
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Annex 9  Results for the analysis of enrofloxacin in egg (material Egg-03) 
 
Enrofloxacin 
Assigned value: 48.0 µg/kg 
Uncertainty of assigned value: 1.47 µg/kg 
Target standard deviation (Horwitz, Thompson):  10.6 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average  sr sW za-score 
2 49.0 51.3 48.6 46.5 48.9 1.27 2.05 0.08 
3 25.9 23.4 21.5 23.6 23.6 1.33 1.76 -2.31 
4 47.4 47.5 59.7 56.2 52.7 1.43 7.49 0.44 
5 53.0 51.0 52.0 54.0 52.5 1.15 1.15 0.42 
6 59.0 66.9 57.0 66.1 62.3 4.92 4.92 1.35 
7 54.8 45.9 51.6 50.8 50.8 3.65 3.65 0.26 
8 40.3 43.0 41.1 43.0 41.9 1.35 1.35 -0.58 
9 62.0 57.0 37.0 52.0 52.0 6.45 11.55 0.38 
11 50.8 47.4 47.2 47.1 48.1 1.39 1.69 0.01 
12 47.0 49.2 45.7 51.9 48.5 2.69 2.69 0.04 
13 17.0 34.0 31.0 47.0 32.3 9.53 11.69 -1.49 
15 40.3 45.1 43.9 41.9 42.8 2.12 2.12 -0.49 
16 61.1 50.6 36.2 47.2 48.8 6.21 10.93 0.07 
17 50.0 50.0 50.0  50.0  50.0 0.00 0.00 0.19 
18 54.0 49.0 46.0 42.0 47.8 2.61 5.62 -0.03 
 RIKILT Report 2008.001 40
Annex 9  Results for the analysis of enrofloxacin in egg (material Egg-03) 
(continued) 
 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of za-score               
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Annex 10  Results for the analysis of oxolinic acid in egg (material Egg-03) 
 
Oxolinic acid 
Assigned value: 73.2 µg/kg 
Uncertainty of assigned value: 1.99 µg/kg 
Target standard deviation (Horwitz, Thompson):  16.1 µg/kg 
Code Replicate 1 Replicate 2 Replicate 3 Replicate 4 Average  sr sW za-score 
2 66.4 69.9 69.8 73.7 70.0 2.14 2.96 -0.20 
4 82.8 78.9 91.7 85.4 84.7 3.02 5.85 0.72 
6 69.0 87.6 67.1 88.9 78.2 11.70 11.70 0.31 
7 61.7 71.0 69.5 63.9 66.5 4.43 4.43 -0.41 
8 76.0 73.8 70.1 76.0 74.0 2.57 2.57 0.05 
9 81.0 72.0 68.0 69.0 72.5 3.70 6.23 -0.04 
13 52.0 62.0 65.0 64.0 60.8 4.10 6.04 -0.77 
15 72.9 75.1 75.9 72.4 74.1 1.69 1.69 0.06 
16 71.8 74.6 72.2 65.9 71.1 2.81 3.55 -0.13 
17  100 100 80  80 90 0.00 14.14 1.04 
18 86.0 75.0 81.0 74.0 79.0 5.32 5.32 0.36 
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Annex 10  Results for the analysis of oxolinic acid in egg (material Egg-03) 
(continued) 
 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of za-score               
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Annex 11  Results for the analysis of flumequine in egg (material Egg-03) 
 
Flumequine 
Assigned value: 124.9 µg/kg 
Uncertainty of assigned value: 4.27 µg/kg 
Target standard deviation (Horwitz, Thompson):  27.3 µg/kg 
Code Replicate 1 Replicate 2 Average  za-score 
2 120.0 116.0 118.0 -0.25 
4 137.0 128.0 132.5 0.28 
6 129.6 139.9 134.8 0.36 
7 130.4 135.2 132.8 0.29 
8 103.1 125.9 114.5 -0.38 
9 99.0 93.0 96.0 -1.06 
11 143.2 133.8 138.5 0.50 
12 111.0 113.0 112.0 -0.47 
13  98.0 111.0  104.5 -0.75 
15 122.3 128.2 125.3 0.01 
16 142.0 147.2 144.6 0.72 
17  80 80  80 -1.64 
18 143.0 121.0 132.0 0.26 
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Annex 11  Results for the analysis of flumequine in egg (material Egg-03) 
(continued) 
 
Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of za-score               
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Annex 12  Overview of obtained za-scores 
 
-3.00
-2.00
-1.00
0.00
1.00
2.00
3.00
CIF -0.18 -3.11 0.04 0.00 0.04 27.38 -0.14 -0.24 0.26 0.01 -0.75 -0.12 0.29 0.00 2.26
ENF 0.08 -2.31 0.44 0.42 1.35 0.26 -0.58 0.38 0.01 0.04 -1.49 -0.49 0.07 0.19 -0.03
OXA -0.20 0.00 0.72 0.00 0.31 -0.41 0.05 -0.04 0.00 0.00 -0.77 0.06 -0.13 1.04 0.36
FLU -0.25 0.00 0.28 0.00 0.36 0.29 -0.38 -1.06 0.50 -0.47 -0.75 0.01 0.72 -1.64 0.26
2 3 4 5 6 7 8 9 11 12 13 15 16 17 18
  
